US FDA clears Minghui Pharma’s IND application to begin global phase ? trials of MHB018A, a subcutaneous single-domain IGF-1R antibody, in thyroid eye disease: Shanghai Tuesday, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback